

# Oliver SchÄffski

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/12059365/publications.pdf>

Version: 2024-02-01

17  
papers

1,006  
citations

759233

12  
h-index

888059

17  
g-index

17  
all docs

17  
docs citations

17  
times ranked

1323  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effects of pay for performance in health care: A systematic review of systematic reviews. Health Policy, 2013, 110, 115-130.	3.0	405
2	Prevalence, utilization, and costs of antiepileptic drugs for epilepsy in Germany—a nationwide population-based study in children and adults. Journal of Neurology, 2012, 259, 2376-2384.	3.6	116
3	Economic evaluation of pay-for-performance in health care: a systematic review. European Journal of Health Economics, 2012, 13, 755-767.	2.8	82
4	Resource Utilization and Costs of Stroke Unit Care in Germany. Value in Health, 2004, 7, 144-152.	0.3	67
5	Trends in resource utilization and prescription of anticonvulsants for patients with active epilepsy in Germany from 2003 to 2013 — A ten-year overview. Epilepsy and Behavior, 2018, 83, 28-35.	1.7	57
6	Adverse drug events in patients admitted to an emergency department: an analysis of direct costs. Pharmacoepidemiology and Drug Safety, 2015, 24, 176-186.	1.9	55
7	What is Germany's experience on reference based drug pricing and the etiology of adverse health outcomes or substitution?. Health Policy, 1998, 44, 253-260.	3.0	40
8	Costs of acute stroke care on regular neurological wards: A comparison with stroke unit setting. Health Policy, 2007, 81, 339-349.	3.0	37
9	Consequences of Implementing a Drug Budget for Office-Based Physicians in Germany. Pharmacoeconomics, 1996, 10, 37-47.	3.3	36
10	Neurologist adherence to clinical practice guidelines and costs in patients with newly diagnosed and chronic epilepsy in Germany. Epilepsy and Behavior, 2016, 64, 75-82.	1.7	26
11	Evaluation of Long-term Clearance Rates of Interventions for Actinic Keratosis. JAMA Dermatology, 2021, 157, 1066.	4.1	24
12	Individualized versus standardized risk assessment in patients at high risk for adverse drug reactions (IDrug) — study protocol for a pragmatic randomized controlled trial. BMC Family Practice, 2016, 17, 49.	2.9	14
13	Potentially inappropriate medication in the elderly in Germany: an economic appraisal of the PRISCUS list. BMC Health Services Research, 2016, 16, 109.	2.2	14
14	Palliative treatment of colorectal cancer in Germany: cost of care and quality of life. European Journal of Health Economics, 2013, 14, 629-638.	2.8	12
15	Long-term recurrence rates of actinic keratosis: A systematic review and pooled analysis of randomized controlled trials. Journal of the American Academy of Dermatology, 2022, 86, 1116-1119.	1.2	11
16	Palliative Treatment of Colorectal Cancer with Secondary Metastasis Resection in Germany - Impact of the Multidisciplinary Treatment Approach on Prognosis and Cost: The Northern Bavaria IVOPAK I Project. Oncology, 2015, 88, 103-121.	1.9	9
17	Bewertung der Einsparpotenziale in der Arzneimitteltherapie durch Dosisanpassung an die Polymorphismen im Cytochrom P450. PharmacoEconomics - German Research Articles, 2012, 10, 69-85.	0.1	1